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Abstract: Phosphodiesterases (PDEs) are enzymes that break down the phosphodiesteric bond 
of the cyclic nucleotides, cAMP and cGMP, second messengers that regulate many biological 
processes. PDEs participate in the regulation of signal transduction by means of a ﬁ  ne regula-
tion of cyclic nucleotides so that the response to cell stimuli is both speciﬁ  c and activates the 
correct third messengers. Several PDE inhibitors have been developed and used as therapeutic 
agents because they increase cyclic nucleotide levels by blocking the PDE function. In particular, 
sildenaﬁ  l, an inhibitor of PDE5, has been mainly used in the treatment of erectile dysfunction 
but is now also utilized against pulmonary hypertension. This review examines the physiologi-
cal role of PDE5 in synaptic plasticity and memory and the use of PDE5 inhibitors as possible 
therapeutic agents against disorders of the central nervous system (CNS).
Keywords: phosphodiesterase 5, NO/cGMP pathway, sildenaﬁ  l, synaptic plasticity, memory, 
Alzheimer’s disease
Phosphodiesterases
Introduction
The cyclic nucleotides, cAMP and cGMP are second messengers that regulate signal 
transduction in various biological systems. They respond to extracellular signals 
(neurotransmitters, hormones, olfactive and luminous signals) and activate intracel-
lular targets such as ion channels, kinases, and transcription factors that trigger the 
cellular response to the message. The extracellular signal is thus transferred by the 
cyclic nucleotides to one of the effector proteins, the most important of these are pro-
tein kinase A (PKA) and protein kinase G (PKG) that, in turn, phosphorylate other 
enzymes or transcription factors (Figure 1).
The levels of cAMP and cGMP are maintained thanks to a balance between produc-
tion, carried out by adenyl cyclase (AC) and guanylyl cyclase (GC), and destruction, 
carried out by phosphodiesterases (PDEs) (Figure 1). PDEs regulate the nucleotide 
signal both in amplitude and duration (spatial and temporal regulation) and modulate 
the “cross talk” between various second messengers. For example many effects of Ca2+ 
on cAMP and cGMP are mediated by the activation of the Ca2+-Calmodulin (Ca2+-CaM) 
dependent phosphorylation of PDEs (Sonnenburg et al 1995).
Over the last few years there has been an increasing number of studies on PDEs. This 
is also thanks to the potential use of these enzymes as targets of drugs that can regulate 
the levels of cyclic nucleotides and the various physiological functions connected to 
them. The recognition of the therapeutic potential of PDEs stems from the ubiquitous 
nature of the second messengers on which these enzymes act. Notwithstanding the 
great potential of these inhibitors, the only pathologies currently treated with PDE 
inhibitors are erectile dysfunction and, more recently, pulmonary hypertension. This 
is due to the complexity of the PDE family and the selectivity of the inhibitors used. 
Various studies are now focusing on the role of PDEs in the CNS and on the potential Neuropsychiatric Disease and Treatment 2008:4(2) 372
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use of PDE inhibitors for nervous system disorders. This can 
be explained by the presence of PDEs in various regions 
of the CNS (Ariano and Appleman 1979; Shinozawa and 
Bitensky 1981; Epplen et al 1982; Shotwell 1983; Kariya and 
Dage 1988; Repaske et al 1993; Lobban et al 1994; Polli 
and Kincaid 1994; Yan et al 1994; Lal et al 1996; Cherry 
and Davis 1999; Shakur et al 2000; Andreeva et al 2001; 
D’Sa et al 2002; Suvarna and O’Donnel 2002; van Staveren 
et al 2002; Houslay and Adams 2003; Kobayashi et al 2003; 
Noyama and Maekawa 2003; Pitts et al 2004; Reyes-Irisarri 
et al 2005) and to the fact that cAMP and cGMP have been 
recognized as secondary messengers of various neuronal 
phenomena such as synaptic plasticity (Dismukes and Daly 
1976; Kandel and Schwartz 1982; Yovell et al 1987; Dixon 
and Atwood 1989; Storozhuk and Balaban 1990; Shibuki 
and Okada 1991; Zhong and Wu 1991; Zhong et al 1992; 
Arancio et al 1995; Wu et al 1995; Southam et al 1996; Lu 
et al 1999; Renger et al 2000; Yoshimura and Kato 2000; Bon 
and Garthwaite 2001, 2003; Esteban et al 2003; Waltereit 
and Weller 2003; Wang and Storm 2003; Barnstable et al 
2004; Feil et al 2005; Makhinson et al 2006; Liu et al 2007; 
Wu et al 2007).
Background
The activity of PDEs was described for the ﬁ  rst time in 1886, 
when Dr Henry Hyde Salter noted that caffeine had bron-
chodilator properties (Boswell-Smith et al 2006). In 1958, 
Sutherland and Rall ﬁ  rst identiﬁ  ed the nucleotide cAMP 
in liver extracts as a second messenger and suggested that 
it could mediate several cellular effects of neurotransmit-
ters and hormones (Sutherland 1958). The existence of an 
enzymatic activity able to catalyze the degradation of this 
molecule was used as one of the initial processes support-
ing the evidence that cAMP is a relevant molecule from 
the physiological point of view (Sutherland 1958). Indeed, 
Sutherland and colleagues discovered that glucagon and 
catecholamines act in the liver by increasing the concentra-
tions of cAMP and that the effect of caffeine on glucagon 
involved the inhibition of cAMP-dependent PDEs (Berthet 
et al 1957; Rall and Sutherland 1958; Butcher and Sutherland 
Figure 1 Cyclic nucleotide signal. The extracellular signal (neurotransmitters, hormones, olfactive and luminous signals) is transferred by the cyclic nucleotides cAMP and 
cGMP to one of the effector proteins, the most important of these are ion channels, protein kinase A (PKA) and protein kinase G (PKG). The kinases, in turn, phosphorylate 
other enzymes or transcription factors such as CREB in the nucleus. Cyclic nucleotides levels are maintained through a balance between production, carried out by adenyl 
cyclase (AC) and guanylil cyclase (GC) from ATP and GTP, respectively, and destruction, carried out by phosphodiesterases (PDEs) that lead to the formation of the inactive 
forms 5'AMP and 5'GMP.
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1962; Exton et al 1971). In 1970 PDEs were differentiated in 
rat and bovine tissue and it was demonstrated that the speci-
ﬁ  city of the reaction was due to the hydrolysis of the cAMP 
and cGMP phosphoester bond (Beavo et al 1970). With the 
development of radionucleotides it was possible to measure 
PDE activity at the substrate level at nearly physiological 
concentrations. From then various PDEs have been isolated, 
puriﬁ  ed and characterized.
Classiﬁ  cation
The superfamily of PDEs is divided into three principle 
classes I, II and III, having different sequences. Class I 
includes all the mammal PDEs (Francis et al 2000) as well 
as Drosophila (Chen et al 1986), Caenorhabditis (Koyanagi 
et al 1998), and yeast (Sass et al 1986, Thomasn et al 1998). 
These enzymes are produced by different genes (Beavo 
et al 1994; Fisher et al 1998) and show high afﬁ  nity for the 
cGMP and /or cAMP molecule. Class II includes enzymes 
from fungi such as Saccharomyces cerevisae (Nikawa et al 
1987), Dictyostelium discoideum (Lacombe et al 1986), 
Schizosaccharomyzes pombe (DeVoti et al 1991), Candida 
albicans (Hoyer et al 1994) and one from bacteria, Vibrio 
ﬁ  scheri (Dunlap and Callahan 1993). PDE class II shares 
a conserved motif containing three histidine residues that 
may be part of a metal ion binding site such as Zn2+ for 
Vibrio ﬁ  scheri (Callahan et al 1995). Class III includes 
only enzymes from prokaryotes such as Escherichia 
coli (Richter 2002). Given that the catalytic site of PDE 
class III is comparable to the purple acid phosphatases, 
these enzymes could be considered as members of a large 
family of structurally related dimetallophosphoesterases 
(Richter 2002).
Twenty-one classes of genes and diverse spliced tran-
scriptional variants for the PDE class I of humans, rats and 
mice have been identiﬁ  ed. They have been classiﬁ  ed into 
11 families based on particular subcellular distributions, 
structural similarities, mechanisms of regulation, amino 
acid sequences, proteic domains and enzymatic proper-
ties among which are speciﬁ  city for the substrate, kinetic 
proprieties, and sensitivity to endogenous regulators and 
inhibitors.
Some PDEs are highly speciﬁ  c for cAMP (PDE4, PDE7, 
PDE8); others are highly speciﬁ  c for cGMP (PDE5, PDE6, 
PDE9), and some have mixed speciﬁ  city (PDE1, PDE2, 
PDE3, PDE10). The nomenclature assigns an Arabic num-
ber to each family with an individual gene expressed by a 
letter and every spliced variant of the gene is identiﬁ  ed by a 
number (ie, PDE5A1).
Structure and mechanism of action
All PDEs are dimeric though the importance of this structure 
is not well known. Each has a core of 270 amino acids 
with a high degree of conservation (25%–35%) among the 
various families that is localized at the C-term and contains 
the catalytic domain of the enzyme. Within each family, 
the sequence of the catalytic domain is highly conserved 
(75%). This makes the identiﬁ  cation of the inhibitors of 
the active site possible and distinguishable between the dif-
ferent families, with the exception of the very high homology 
between PDE5 and PDE11 that makes, for example, some 
inhibitors of PDE5 such as tadalaﬁ  l also active against 
PDE11 (Weeks et al 2005).
Most PDEs have a regulatory domain at the N-term 
that varies among the families and provides the sites for 
dimerization, phosphorylation and modulatory bonds such 
as Ca2+-CaM and cGMP. For example, PDE1 contains a 
Ca2+/CaM-binding domain that activates the enzyme. About 
half of the genetic families have a GAF domain (PDE2, 
PDE5, PDE6, PDE10, PDE11) that mediates the allosteric 
regulation of the bond with cGMP. The other PDEs belong 
to NON-GAF-PDEs. It is believed that some PDEs also 
possess an auto-inhibitory domain in the structure of the 
enzyme that is detected by some PDE activators (Jin et al 
1992; Sonnenburg et al 1995).
PDEs are ubiquitously distributed and most of them have 
been found in CNS (for a review see Bender and Beavo 
2006). The cGMP-hydrolysing PDE2, PDE5, and PDE9 and 
the cAMP-hydrolysing PDE4 and PDE7 are located in the 
hippocampus where they are likely to be involved in memory 
and/or long-term potentiation (LTP; Beavo 1995; Barad et al 
1998; Houslay 2001; Mirò et al 2001; Boess et al 2004; 
Gong et al 2004; Van Staveren et al 2004; Wunder et al 2005; 
Reyes-Irisarri et al 2005). PDE6 has also been found in the 
hippocampus, although it does not affect synaptic transmis-
sion or synaptic plasticity (Kuenzi et al 2003).
PDEs hydrolyze the phosphodiesteric bond of cyclic 
nucleotides between the atoms of phosphorus and oxygen in 
position 3' with the inversion of the phosphorus atom con-
ﬁ  guration (Burgers et al 1979; Goldberg et al 1980) and the 
consequent formation of adenosin monophosphate (AMP) 
and guanosin monophosphate (GMP), which are recycled as 
substrates for the formation of ATP and GTP.
PDEs are regulated by means of 3 principal mechanisms: 
i) Availability of the substrate, such as the stimulation of PDE 
activity after the increase of the levels of cyclic nucleotides or 
after alteration of the ratio of hydrolysis between one nucleo-
tide and another; ii) Regulation of the intracellular signal Neuropsychiatric Disease and Treatment 2008:4(2) 374
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by extracellular signals (ie, phosphorylation); iii) Feedback 
regulation (Corbin and Francis 1999).
Phosphodiesterase 5
Characteristics
PDE5 is a cGMP-speciﬁ  c enzyme that hydrolyzes cGMP. 
The cyclic nucleotid plays a fundamental role in signal 
translation. It stimulates the relaxation of smooth muscle, 
the degranulation of neutrophils, inhibits platelet aggregation 
and initiates translation of the visual signal (Furchgott and 
Vanhoutte 1989; Hofmann et al 1992; Lincoln and Cornwell 
1993; Garbers and Lowe 1994; Moro et al 1996; Lohmann 
et al 1997; Corbin and Francis 1999). cGMP is one of the 
targets for the action of nitric oxide (NO), a particular neu-
rotransmitter, which is the main subject of this review.
As mentioned above, the tissue levels of cGMP depend 
on the balance between the activity of GC that catalyzes the 
formation of cGMP from GTP, and from PDEs that catalyze 
the breakdown of cGMP into GMP.
PDE5 was puriﬁ  ed in 1980 by Francis and colleagues from 
rat lungs (Francis et al 1980; Francis and Corbin 1988) and 
cloned in 1993 by McAllister-Lucas (McAllister-Lucas et al 
1993). Two spliced variants have been recognized (Loughney 
et al 1998; Yanaka et al 1998). At ﬁ  rst it was believed that 
PDE5 was part of PDE6 (PDE of the photoreceptors) given 
its notable similarity. However, considering that the sequence 
identity is less than 60% (McAllister-Lucas 1993), PDE5 was 
subsequently classiﬁ  ed as a separate family.
The tissue distribution of PDE5 generally coincides 
with that of PKG, probably because both enzymes are the 
principal intracellular receptors of cGMP. Moreover, PKG 
is an excellent in vitro catalyst for the phosphorylation of 
PDE5 (Thomas et al 1990). PDE5 has a typical cytosolic 
localization with high levels in smooth muscle, platelets, 
kidney and in some zones of the CNS (Francis and Corbin 
1999; Kotera et al 2000; van Staveren et al 2004; Dolci et al 
2006; Menniti et al 2006).
The NO/cGMP pathway
To understand the function of PDEs it is necessary to know 
the pathway by which they act. cGMP is produced by the 
GC enzyme, an NO target. NO is a molecule that has been 
widely studied since 1800, when the potential therapeutic role 
of nitroglycerin with its vasodilatatory effect was discovered 
for the treatment of angina pectoris (Brunton 1867). It was 
later discovered that the effect of NO was mediated through 
cGMP synthesis, which activated vascular reactions. NO was 
identiﬁ  ed in the nervous system in 1988 as a molecule that 
was able to mediate the increase of cGMP after the activation 
of the glutamatergic receptor N-methyl-D-aspartate (NMDA) 
(Garthwaite and Boulton 1995).
Over the last few years the function of NO as a neu-
rotransmitter has been studied (Puzzo et al 2006). A particular 
characteristic is its capacity to function as a retrograde 
neurotransmitter able to transfer information from the 
post- to the pre-synaptic terminal. This completely revolu-
tionized the concept of synaptic transmission and neuronal 
communication.
The formation of NO is catalyzed by the NO synthase 
enzyme (NOS) of which different variants exist: i) the Ca2+-
dependent constitutive form (c-NOS), consisting of the 
endothelial form (e-NOS) or type III and the neuronal form 
(n-NOS) or type I, present in the endothelium, and in glial and 
neuronal cells that produce NO in physiological conditions; 
ii) the Ca2+-independent inducible form (i-NOS) or type II, 
present in macrophages, hepatocytes, smooth muscle, glia 
and endothelium that produces NO following immunological 
stimuli (ie, interferon γ, tumor necrosis factor α, LPS).
The biological receptor of NO is GC, a ubiquitous enzyme 
that, once activated, catalyzes the formation of cGMP. cGMP 
has various targets among which are cGMP-dependent chan-
nels, PKG, and PDEs. PKG are mediators of signal translation 
(Lohmann 1997). PKGI, composed of the α and β subunits, 
is ubiquitous; the monomeric PKGII is expressed in various 
tissues such as the lung, kidney, testicle and brain. cGMP 
can also activate the cAMP pathway acting on the cAMP 
binding site and PKA (Tsukada et al 2002).
Structure and function of PDE5
The human gene for PDE5 has been mapped in the 4q26 
chromosome, which contains 24 exons that occupy approxi-
mately 100 k bases (Yanaka et al 1998). The enzyme PDE5 is 
an active homodimer, with an MW of ~ 3000 kd (Figure 2). 
Each monomer contains a catalytic domain in the C-term with 
2 binding sites for Zn2+. These are involved in the process of 
catalysis and it is believed that the catalytic activity of PDE 
4, 5 and 6 is sustained by submicromolar concentrations of 
Zn2+ (Francis et al 1994; Percival et al 1997; He et al 2000). In 
the C-term catalytic domain there is an allosteric binding site 
for cGMP and in the N-term regulatory domain there are two 
allosteric binding sites called GAF a and b domains (McAl-
lister-Lucas et al 1995). It is likely that GAFa is responsible 
for the allosteric binding of cGMP (Liu et al 2002; Zoraghi 
et al 2005). Both the allosteric and catalytic sites are highly 
speciﬁ  c for cGMP. The catalytic domain has high afﬁ  nity 
for cGMP (Km ~ 1–5 µM, compared with Km ~ 300 µm of Neuropsychiatric Disease and Treatment 2008:4(2) 375
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cAMP). Binding of cGMP to the allosteric site is necessary 
for the speciﬁ  c phosphorylation of Ser-92 by PKG. The bond 
not only activates the catalytic function but increases the bind-
ing afﬁ  nity for cGMP (Corbin et al 2000; Francis et al 2002; 
Zoraghi et al 2005). The two allosteric sites homologous for 
cGMP (a and b) are kinetically distinct. Both sites need to 
bind to cGMP for PDE activation. The increased interaction 
of cGMP with the catalytic site increases the binding of cGMP 
in the allosteric site thus increasing the phosphorylation of the 
enzyme promoting a further increase of cGMP cleavage.
There are three isoforms of PDE5 (PDE5A1-PDE5A3) 
which are distinguished based on their N-term sequence. 
PDE5A1 and PDE5A2 are ubiquitous, but PDE5A3 is 
speciﬁ  c to smooth muscle (Lin 2004). A single PDE5A 
gene encodes for the 3 isoforms and the initial three exons 
(A1-A3-A2) encode the isoform-speciﬁ  c sequences. The 
promoters are responsive to cGMP or cAMP stimulation, 
and several studies have demonstrated regulation of PDE5 
expression possibly through these promoters (Lin et al 
2006). The potential role of different PDE5A promoters in 
catalytic domain
P
NH2
a b
COOH
A
B
A
B
allosteric binding
NH2
P
COOH
Zn2+-binding sites
Figure 2 Schematic representation of PDE5 structure. PDE5 is a homodimer containing, in each monomer, a C-term catalytic domain and an N-term regulatory domain. The 
catalytic domain contains 2 Zn2+-binding sites (A and B) and an allosteric binding site for cGMP. The regulatory domain contains two allosteric binding sites called GAF a and b, 
domains responsible for the allosteric binding of cGMP. The occupation of the allosteric site by cGMP is necessary for the speciﬁ  c phosphorylation of Ser-92 by PKG.Neuropsychiatric Disease and Treatment 2008:4(2) 376
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the effect of PDE5 inhibitors is currently being investigated 
(Lin 2004). Moreover, the study of the 3 isoforms may be 
relevant for future drug development as our knowledge of 
PDE structure-function relations increases.
The principal functions of PDE5 consist of modulat-
ing hemodynamics affecting the contracted state of vessel 
cells by regulating the phasic nature of smooth muscle 
physiology (Jackson et al 1999; Rybalkin et al 2003; Pri-
sant 2006; Cawley et al 2007). PDE5 exerts its action in 
all smooth muscle districts modulating, other then the tone 
of blood vessels, the contractile state of organs such as the 
penis, uterus, and intestines. However, its function has 
been mainly studied in the corpora cavernosa and in the 
pulmonary system given the therapeutical implication of 
the use of PDE5 inhibitors aimed at provoking a relaxation 
of these organs to alleviate erectile dysfunction and pul-
monary hypertension (Ziegler et al 1995; Cohen et al 1996; 
Weimann et al 2000; Lewis and Semigran 2004; Toward 
et al 2004; Larrue et al 2005). PDE5 plays also a key role 
in the peripheral vessel system by regulating systemic 
blood pressure. Moreover, PDE5 is involved in the regula-
tion of the response to the atrial natriuretic peptide (ANF) 
(Weishaar et al 1990) and it might regulate Na+ retention 
(Ghali-Ghoul et al 2007).
Figure 3 shows the effects exerted by cGMP in some 
target organs and the possible therapeutical application of 
PDE5 inhibitors leading to an increase of cGMP.
PDE5 Inhibitors
Sildenaﬁ  l and other PDE5 inhibitors
For many years, nonselective PDE5 inhibitors such as 
caffeine, theophylline and IBMX have been used to 
investigate the physiological effects of cyclic nucleotides. A 
more selective inhibitor called sildenaﬁ  l has now attracted 
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Figure 3 cGMP functions and possible therapeutic use of PDE5 inhibitors. PDE5 inhibitors block the degradation of cGMP (bottom panel) leading to an increase of the 
level of cGMP that can exert its action on several target organs. On the right side, both the approved and possible (question mark) therapeutical applications of PDE5 
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the attention of many researchers. Sildenaﬁ  l is the active 
agent of the widely diffused drug Viagra used for erectile 
dysfunction (ED).
Sildenaﬁ  l, initially synthesized with the aim of treating 
arterial hypertension and angina pectoris, was the ﬁ  rst drug 
approved by the USA Food and Drug Administration for 
the treatment of ED (FDA 1998). To date it is the principle 
treatment for ED given its risk-beneﬁ  t ratio. Sildenaﬁ  l, with 
the commercial name of Revatio (Pﬁ  zer), was also approved 
for the therapy of hypertension of the pulmonary artery in 
June 2005. Various studies indicate that sildenaﬁ  l can offer 
new strategies for the treatment of other pathologies such as 
multiple sclerosis (MS), pain, and memory loss (Uthayathas 
et al 2007).
Thanks to these discoveries, thousands of compounds 
have been synthesized and screened against PDE5. Reported 
PDE5 inhibitors can be divided into the following classes: 
1) cGMP-based, represented by sildenaﬁ  l (Viagra) and 
vardenafil (Levitra) (Pfizer, Bayer, Sheering-Plough), 
2) β-carboline – derived, represented by tadalaﬁ  l (Cialis) 
(Lilly, Johnson&Johnson [J&J], 3) quinazoline and isoquino-
linone derivatives (Bristol-Myers-Squibb [BMS], Japan), and 
4) phthalazine derivatives (BMS, Japan).
Among these vardenaﬁ  l and tadalaﬁ  l are considered the 
most potent inhibitors (Kulkarni and Patil 2004). Vardenaﬁ  l 
is a new drug used for erectile dysfunction. It has an IC50 of 
0.7 nM for PDE5 with respect to other PDEs (PDE1: 180 nm; 
PDE2, 3, 4 1 µm; PDE6: 11 nm) (Saenz de Tejada et al 
2001). The inhibitory potential of vardenaﬁ  l towards PDE5 
is 5 times greater than sildenaﬁ  l.
Differently than sildenaﬁ  l and vardenaﬁ  l, which are 
cGMP-based inhibitors, tadalaﬁ  l is a β-carboline-derived 
drug with no effect on PDE1 (selectivity ratio 2000) and 
on PDE6 (selectivity ratio 1000), and an IC50 against PDE5 
of 5.0 nM (Daugan et al 2003). Tadalaﬁ  l is a second genera-
tion oral drug. It acts quickly and its effects last longer than 
sildenaﬁ  l (Forgue et al 2006).
Sildenaﬁ  l, vardenaﬁ  l, and tadalaﬁ  l are rapidly absorbed 
in the gastrointestinal tract at the level of the small intestine. 
The half life of sildenaﬁ  l and vardenaﬁ  l is ~ 3–4 h whereas 
tadalaﬁ  l has a half-life of ~ 18 h (Kulkarni and Patil 2004; 
Forgue et al 2006). They are all metabolized by means of the 
p450 cytochrome system and also eliminated by this system 
at the hepatic level.
The possible use of these drugs in the CNS is also 
related to their ability to cross the blood – brain barrier 
(BBB). Sildenaﬁ  l is reported to clearly cross the BBB 
(FDA 1998). Evidence for the ability of vardenaﬁ  l to cross 
the BBB is indirect (Prickaerts et al 2004), and tadalaﬁ  l 
is unlikely to cross it (personal communication from V. 
Florio at Icos).
These drugs can have side effects such as headaches, 
facial ﬂ  ushing, nasal congestion, and dyspepsia. These effects 
are, however, transitory and disappear with the suspension of 
the drug. Moreover, both sildenaﬁ  l and vardenaﬁ  l can act on 
PDE6, which is present in the retina, thus high doses can cause 
vision problems. Tadalaﬁ  l, moreover, can inhibit PDE11. 
These drugs are not suitable for cardiopathic subjects, due 
to the possible vasodilatatory effects, and hypotensives, as 
well as in subjects who suffer from orthostatic hypotension, 
aortic stenosis, obstructive hypertrophic cardiomyopathy, 
and retinitis pigmentosa (Kulkarni and Patil 2004).
PDE5 inhibitors and neurogenesis
Neurogenesis is the production of new neurons, and it is 
a process that is active mostly during prenatal develop-
ment, though new neurons are also produced during adult 
life in some areas of the brain such as the subventricular 
zone (SVZ) and the subgranular zone (SGZ) of the dentate 
gyrus of the hippocampus of mammals, including humans, 
and other species (Altman and Das 1965; Eriksson et al 
1998; Gould et al 1999; Zhao et al 2003; Taupin 2006; 
Kim and Szele 2007). The functional signiﬁ  cance of adult 
neurogenesis is just beginning to be understood and there is 
considerable disagreement in literature. There is evidence 
showing that adult neurogenesis in the hippocampus plays a 
role in synaptic plasticity (Sandeman and Sandeman 2000; 
Bruel-Jungerman et al 2006, 2007; Schmidt-Hieber et al 
2004) and memory (Shors et al 2001, 2002; Snyder et al 
2005; Bischofberger 2007; Bruel-Jungerman et al 2007; 
Dupret et al 2007; Epp et al 2007; Van der Borght et al 
2007). Higher levels of neurogenesis resulting from an 
enriched environment are reported to correspond to better 
acquisition of the Morris Water Maze task in mice (Kem-
permann et al 2002) and new neurons have been shown to 
be necessary for consolidation of memory after water maze 
training (Snyder et al 2005). It seems that new neurons can 
increase mnemonic capacity (Becker 2005), reducing the 
interference between newly formed memories (Wiskott 
et al 2006), and adding spatial-temporal details to the new 
memory (Aimone et al 2006).
It also appears that neurogenesis plays a key role in 
the regulation of stress and that this is in turn linked to 
the integrity of the hippocampus. Some studies have, in 
fact, demonstrated that the positive activity of some anti-
depressants is linked to the stimulation of hippocampal Neuropsychiatric Disease and Treatment 2008:4(2) 378
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neurogenesis (Malberg et al 2000; Manev et al 2001) and that 
inhibition of hippocampal neurogenesis induced by radiation 
blocks the effects of anti-depressants (Santarelli et al 2003). 
Other studies have shown that memory is correlated with 
mood disorders, particularly with depression, and that mood 
is regulated by the phenomena of neurogenesis and synaptic 
plasticity (Castren et al 2005; Paizanis et al 2007).
Hippocampal neurogenesis is controlled by various fac-
tors such as physical exercise, stress, sleep, environmental 
conditions, hormones (testosterone), neurotransmitters 
(serotonin) and intrinsic growth factors (Cameron and Gould 
1994; Lledo et al 2006), which can affect different stages of 
the neurogenetic process. Neurogenesis is also stimulated 
by hippocampal or cortical damage (Covolan et al 2000; 
Blumcke et al 2001; Jiang et al 2001; Jin et al 2001) and 
could be modiﬁ  ed by pathologies such as Alzheimer’s disease 
(Kuhn et al 2007).
It is interesting to note that some studies have shown that 
sildenaﬁ  l plays a role in potentiating neurogenesis through 
the increase of cGMP levels. NO inﬂ  uenced sensory-induced 
neurogenesis (Cayre et al 2005) and prenatal development 
of the brain through cGMP (Chen et al 2004). Furthermore, 
neuronal growth decreases with age in parallel with the reduc-
tion of cGMP levels (Taddei et al 2001). Several studies have 
demonstrated that sildenaﬁ  l can be used to stimulate neuro-
genesis after stroke. In rats, Sildenaﬁ  l induces neurogenesis, 
reduces neurological deﬁ  cit and promotes the functional 
recovery after stroke and focal cerebral ischemia (Zhang 
et al 2002; 2006b). Tadalaﬁ  l has also been used to improve 
neurogenesis in an embolic model of stroke in rats (Zhang 
et al 2006a). Thus, it is possible that in the future PDE5 
inhibitors might be used to stimulate neuronal function and 
improve neurogenesis in older subjects or in patients affected 
by AD and other disorders characterized by hippocampal 
memory impairment.
PDE5 inhibitors and memory
Role of NO/cGMP in synaptic plasticity and memory
Synaptic plasticity is an active phenomenon consisting of 
all the structural and/or neuronal functional modiﬁ  cations 
that allow adaptation to new situations (Hebb 1949). It is 
thought to be at the bases of learning and memory and occurs 
in various cerebral structures such as the hippocampus, the 
cerebral cortex and the cerebellum.
The most studied form of synaptic plasticity is long-term 
potentiation (LTP) occurring at the excitatory synapses 
of the hippocampus and consisting of an increase in 
the amplitude of the post-synaptic excitatory potentials 
(EPSPs) after high frequency stimulation (tetanus) of the 
afferent ﬁ  bers. LTP can be detected in various areas of the 
hippocampus but it is mostly observed in the CA1 pyra-
midal cells and pre-synaptic ﬁ  bers forming the Schaffer 
collateral, which is implicated in learning and memory. 
Many studies support the hypothesis that LTP underlies 
memory (Larson et al 1986; Morris et al 1986; Rose and 
Dunwiddie 1986; Diamond et al 1988; Greenstein et al 
1988; Buchs and Muller 1996; Lynch 2004), although the 
complex mechanisms involved in memory have not yet 
been fully clariﬁ  ed. Various studies have shown that LTP 
and memory depend on a cellular cascade stimulated by an 
increase of the intracellular concentrations of cAMP with 
the subsequent activation of PKA and the phosphorylation 
of the cAMP responsive element binding protein (CREB) 
(Bourtchuladze et al 1994; Huang and Kandel 1994; Yin 
et al 1994; Robertson and Sweatt 1996; Abel et al 1997; 
Montminy 1997; Murphy and Segal 1997; Shieh et al 1998; 
Tao et al 1998; Otmakhova et al 2002; Stanciu et al 2001; 
Gooney et al 2002). Besides cAMP, a fundamental role is 
played by the cGMP/PKG/CREB pathway that seems to act 
in parallel with the cAMP/PKA/CREB pathway.
Studying the role of the cGMP pathway in memory stems 
from the crucial need to identify pre- and post-synaptic 
mechanisms in LTP. In the early 1990s it was suggested that 
the induction of LTP involves a retrograde message released 
at the post-synaptic level and acting at the pre-synaptic level 
(Bohme et al 1991; O’Dell et al 1991; Schuman and Madison 
1991). Various studies have shown that NO is necessary for 
LTP: i) inhibitors of NOS block LTP and this inhibition is 
corrected administering precursors of NO (Schuman and 
Madison 1991; Gribkoff and Lum-Ragan 1992; Haley et al 
1992; Bohme et al 1991, 1993; Bon et al 1992); ii) knock-out 
mice for nNOS and eNOS show LTP impairment (Son et al 
1996); iii) exogenous application of NO induces plasticity 
(Zhuo et al 1993; Arancio et al 1996; Bon and Garthwaite 
2001); and iv) NO is able to stimulate the release of sponta-
neous pre-synaptic neurotransmitter release in cell cultures 
(O’Dell et al 1991).
Given that cGMP is a downstream effector of NO, the 
involvement of the cGMP/PKG/CREB pathway has also 
been investigated. These studies showed that: i) inhibitors of 
GC block the induction of LTP (Haley et al 1992; Zhuo et al 
1994; Andreasen et al 2003); ii) analogs of cGMP produce 
potentiation despite the block of upstream NMDA receptors 
and NO release (Haley et al 1992; Arancio et al 1995); and 
iii) inhibitors of GC and of PKG block LTP (Arancio et al 
1995, 2001).Neuropsychiatric Disease and Treatment 2008:4(2) 379
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Behavioral studies have also shown that NO is involved 
in the phenomenon of learning and memory (Hawkins 1996; 
Susswein et al 2004). Bohme and colleagues (1991) demon-
strated that the inhibition of endogenous NO impaired spatial 
learning tested with a radial arm maze and olfactive memory, 
but had no effect on shock-avoidance learning. Studies on 
nNOS knockout mice or by using inhibitors of NOS have 
shown an impairment of spatial performance with the Morris 
water maze (MWM) and object recognition memory in rats 
(Chapman et al 1992; Prickaerts et al 1997; Zou et al 1998; 
Kirchner et al 2004; Koylu et al 2005). Moreover, the block 
of spatial memory obtained by blocking the NMDA recep-
tors could be restored using NO donors or cGMP analogs 
(Yamada et al 1996). The effect of NO on behavior is medi-
ated by the cGMP/PKG pathway. In fact, passive avoidance 
learning in rats increased cGMP levels in the hippocampus 
and the administration of 8-Br-cGMP, a cGMP analog 
(Bernabeu et al 1996), or zaprinast, a selective cGMP PDE 
inhibitor (Prickaerts et al 1997), improved memory. On the 
other hand, the post-training inhibition of GC or PKG activity 
blocked memory formation (Bernabeu et al 1996).
Role of NO/cGMP in Alzheimer’s disease
One of the most widespread and invalidating pathologies 
that causes a deﬁ  cit of cognitive functions is Alzheimer’s 
disease (AD). AD is a progressive neurodegenerative disorder 
characterized by loss of memory and behavioral problems 
leading to dementia. The advanced stages of the pathology are 
characterized by the presence of senile plaques at the cerebral 
level, principally made up of beta-amyloid peptide (Aβ) and 
neuroﬁ  brillary tangles (Selkoe 1994). However, the early 
symptoms, which consist in the loss of memory, also occur 
without signs of cerebral alterations and are probably due to a 
synaptic dysfunction caused by Aβ (Cullen et al 1997; Lambert 
et al 1998; Itoh et al 1999; Chen et al 2000; Vitolo et al 2002; 
Walsh et al 2002). It appears, in fact, that Aβ causes a deﬁ  cit 
at the excitatory neurotransmission level causing a synaptic 
dysfunction that precedes the structural alteration with a loss 
of neurons (Selkoe 2002).
Aβ has various targets that have been well studied and 
that could identify new therapeutic approaches (Mattson 
1997). Various studies suggest that the NO/cGMP pathway 
can be involved in the pathogenesis of AD. These studies have 
indicated a dual role for NO: neuroprotective and neurotoxic. 
Some authors have shown that by acting on the NO/cGMP 
pathway with NO donors, cGMP analogs, or PDE inhibitors, 
it is possible to obtain an improvement of the Aβ-induced 
damage both at the level of the CNS and the vascular system 
(McCarty 1998; Mattson et al 1999; Paris et al 1999; Troy 
et al 2000; Wirtz-Brugger and Giovanni 2000). In particular, 
inhibition of PDEs appears to block the vasoconstriction and 
inﬂ  ammation of the microglia induced by Aβ (Paris et al 
2000). Given that the NO/cGMP/PKG pathway is involved in 
LTP, a phenomenon that is altered in the early phases of the 
pathology in transgenic mouse models (Trinchese et al 2004), 
it has been demonstrated that this pathway has a protective 
role with regards to Aβ-induced LTP impairment (Puzzo 
et al 2005). Moreover, an enhancement of this pathway has 
been associated with a restoration of the phosphorylation of 
CREB (Puzzo et al 2005), a transcription factor linked to 
memory (Bourtchuladze et al 1994; Yin et al 1994; Lonze 
and Ginty 2002). The potential neurotoxic role of NO has 
been focused on in many studies showing that activation 
of iNOS in microglia in response to Aβ is involved in AD 
pathogenesis (Parks et al 2001; Tran et al 2001; Haas et al 
2002; Xie et al 2002). A unifying hypothesis that combines 
studies on protective and toxic roles of NO is that the two 
constitutive NOS, n-NOS and e-NOS, have a potential neu-
roprotective role while i-NOS mediates the oxidative stress 
induced by NO.
Use of PDE5 inhibitors as a memory enhancer
It has been shown that the PDE5 inhibitor sildenaﬁ  l inﬂ  u-
ences long-term memory retention in mice by modulating 
mechanisms involved in memory storage (Baratti and Boccia 
1999). Moreover, the inhibition of PDE5 improves object 
memory (Prickaerts et al 2002, 2004; Rutten et al 2005) 
and counteracts spatial learning impairment induced by 
NOS inhibition (Devan et al 2005, 2006) and by blockade 
of cholinergic muscarinic receptors in rats (Devan et al 
2005). Other studies have shown that sildenaﬁ  l produces 
a dose-dependent improvement of memory in mice tested 
with elevated plus maze (Singh and Parle 2003). Sildenaﬁ  l 
effects have also been tested on selective auditory attention 
and verbal recognition memory in humans (Schultheiss et al 
2001). Despite the fact that no differences in behavioural 
patterns were found, sildenaﬁ  l enhanced the ability to focus 
attention on streams of auditory stimuli, as revealed by an 
improvement of the typical ERP components.
As mentioned above, Aβ has been implicated as a key 
molecule in AD pathogenesis. Several studies have tried to 
clarify the second messenger pathway(s) by which Aβ affects 
synaptic plasticity and memory. The cAMP/PKA/CREB 
pathway has been found to be involved in Aβ-induced LTP 
impairment (Vitolo et al 2002; Gong et al 2004). Rolipram, 
a PDE4 inhibitor increasing cAMP levels, reversed the Neuropsychiatric Disease and Treatment 2008:4(2) 380
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inhibition of PKA activity and CREB phosphorylation 
most probably by favoring the dissociation of regulatory 
and catalytic subunits of PKA and the restoration of PKA 
activity (Vitolo et al 2002). Moreover, treatment with Rolip-
ram re-estabilished LTP and contextual learning in animal 
models of AD (APP/PS1 mice) and, most importantly, this 
beneﬁ  cial effect could be extended beyond the duration of 
the administration (Gong et al 2004). Aβ has also been found 
to downregulate the NO pathway leading to a reduction in 
CREB phosphorylation through reduced activation of PKG 
(Puzzo et al 2005). Recent studies have shown that nitrates 
might counteract microglia activation and Aβ deposits (Troy 
et al 2000; Jantzen et al 2002) and NO-mimetic molecules 
may reverse cognitive impairment in AD (Thatcher et al 
2002, 2005). Thus, enhancers of the cAMP/PKA/CREB or 
NO/cGMP/PKG/CREB pathways might represent novel 
classes of compounds that could effectively counteract 
disease progression by acting at the downstream level of 
Aβ production. PDE inhibitors have been proposed to be 
employed as memory enhancers (Blokland et al 2006; Rose 
et al 2005; Rutten et al 2007). With regard to the use of these 
inhibitors, it is noteworthy that the development of PDE4 
inhibitors as CNS drugs has been a very difﬁ  cult endeav-
our because of undesirable side effects, or lack of efﬁ  cacy 
at the doses used to avoid side effects. For instance, the 
PDE4 inhibitor Rolipram, used for its anti-depressant and 
anti-inﬂ  ammatory effects, causes a number of side-effects 
(especially nausea and headache), which have limited its 
therapeutic use (Souness et al 2000). Thus, it is possible that 
inhibiting PDE5s might be an alternative and perhaps more 
suitable strategy than inhibiting PDE4s to develop a drug 
targeted to CNS and memory.
Based on these ﬁ  ndings, and considering that the current 
therapy for AD (acetylcholinesterase inhibitors, NMDA 
antagonists, drugs that reduce Aβ levels or its oligomeriza-
tion, formation of neuroﬁ  brils, oxidative stress, and inﬂ  am-
mation of the microglia; Schenk et al 1999; Nakagami et al 
2002; Walsh et al 2005) has a limited efﬁ  cacy, our group is 
currently studying the possibility of using PDE5 inhibitors 
in AD. Acting on a speciﬁ  c Aβ target such as the NO/cGMP/
PKG pathway through PDE5 inhibitors could represent a 
useful therapeutic approach to block the disease at an early 
stage, before structural damage occurs. Moreover, it appears 
that Aβ, other than accumulating in the brain, is also pres-
ent in the blood stream where it can cause phenomena of 
vasoconstriction that lead to arterial hypertension (Basun 
et al 2002; Andreasen et al 2003; Kalaria 2003; Suhara et al 
2003; Price et al 2004; Smith et al 2004), often associated 
with AD (Pasquier and Leys 1998; Gentile et al 2004; Price 
et al 2004). It would thus be interesting to use PDE5 inhibi-
tors to contrast both the neurological and vascular symptoms 
associated with this pathology.
Use of PDE5 inhibitors in other nervous 
system diseases
All PDEs are expressed at the level of the nervous system 
suggesting that they could be targeted by some drugs used 
for pathologies of the nervous system. Sildenaﬁ  l has been 
proposed for pain therapy both in humans and animals 
(Asomoza-Espinosa et al 2001; Jain et al 2001; Patil et al 
2004; Ambriz-Tututi et al 2005). Chronic neuropathic pain, 
often associated with nervous system diseases, is very dif-
ﬁ  cult to treat therapeutically (Pezet and McMahon 2006). 
Opioids have been found ineffective and the possible use of 
a low dose of ketamine produces a transient amelioration 
(Eide et al 1995; Mathisen et al 1995; Wiesenfeld-Hallin 
1998; Pedersen et al 2006), but can also give memory impair-
ment and psychotic symptoms (Krystal et al 1994; Malhotra 
et al 1996). Recent studies have shown that sildenaﬁ  l can be 
used for the treatment of pain in animal models (Asomoza-
Espinosa et al 2001; Jain et al 2001; Patil et al 2004; Ambriz-
Tututi et al 2005) because of the peripheral accumulation 
of cGMP that it is likely to have an anti-nociceptive effect 
(Jain et al 2003). A further interesting application would be 
the treatment of diabetic neuropathy in which alteration in 
nNOS seems to be a key factor (Patil et al 2004).
Sildenaﬁ  l has also been shown to have a potential applica-
tion in MS, a chronic inﬂ  ammatory CNS disease character-
ized by demyelinization of nerve cells that leads to severe 
psychomotor disability. There is no deﬁ  nitive therapy for MS 
but the different approaches (interferon, glatiramer acetate, 
novantrone, natalizumab, corticosteroids, and miorelax-
ants) aim to cure the symptoms and the progression of the 
pathology. Given its role in neuroprotection and neurogenesis 
(see above), sildenaﬁ  l might have a potential application in 
patients with MS. Moreover, it has been demonstrated that 
sildenaﬁ  l can be useful to successfully treat ED in MS (Fowler 
et al 2005) and other neurological disorders such as spina 
biﬁ  da and Parkinson’s disease (Nehra and Moreland 2001).
Conclusions
This review summarizes the effect of PDE5 in physiologi-
cal processes and, in particular, on synaptic plasticity and 
memory. Given the widespread distribution of PDE5, the use 
of selective PDE5 inhibitors such as sildenaﬁ  l, vardenaﬁ  l, 
and tadalaﬁ  l has been widely investigated. The use of PDE5 Neuropsychiatric Disease and Treatment 2008:4(2) 381
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inhibitors is now approved by the FDA for the therapy of ED 
and pulmonary hypertension, however, many other diseases 
might take advantage of these drugs. Among these, particular 
attention should be given to CNS diseases characterized by 
cognitive impairment such as AD. Moreover, given the role 
of sildenaﬁ  l in neurogenesis, CNS diseases such as mood 
disorders, MS and stroke might be approached with PDE5 
inhibitors. The role of PDE5 on nociception should be another 
ﬁ  eld of further investigation.
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